絞り込み

17897

広告

Successful treatment of refractory low grade duodenal lymphoma with rituximab, an anti-CD20 monoclonal antibody.

著者 Ahmed S , Singh A , Krauss J , Wentz T , Gunaratnam NT
Am J Clin Oncol.2003 Aug ; 26(4):408-10.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Department of Internal Medicine, St. Joseph Mercy Hospital, Ann Arbor, Michigan 48195, USA.

スターを付ける スターを付ける     (29view , 0users)

Full Text Sources

Medical

Miscellaneous

Duodenal lymphoma accounts for a small percentage of gastrointestinal tumors and has a very poor prognosis. The majority of patients have little or no cure with limited time of remission. Median survival is 5 to 10 years, and most patients die of lymphoma, its complications, or complications of therapy. We report a patient with lymphoma refractory to treatment with cyclophosphamide, vincristine, and prednisone, who was successfully treated with rituximab, a CD-20 monoclonal antibody.
PMID: 12902896 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード